Difference between revisions of "Staging page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Blanked the page)
Tag: Blanking
 
(67 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
<span id="BackToTop"></span>
 
−
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
 
−
[[#top|Back to Top]]
 
−
</div>
 
−
{| class="wikitable" style="text-align:center; width:50%;"
 
−
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#4a1486"|'''Section editor'''
 
−
|-
 
−
|style="background-color:#F0F0F0"|[[File:Hilal.jpg|frameless|upright=0.3|center]]
 
−
|<big>Talal Hilal, MD<br>University of Mississippi<br>Jackson, MS</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]] [https://twitter.com/THilalMD THilalMD]
 
−
|-
 
−
|}
 
−
Unlike the other chemotherapy regimen pages, this one is not disease-specific. Rather, this is a gathering point for all autologous hematopoietic stem cell transplant (HSCT) conditioning regimens. Unless otherwise specified, the day before HSCT is day -1, the day of HSCT is day 0, and the day after HSCT is day +1.
 
−
{| class="wikitable" style="float:right; margin-right: 5px;"
 
−
|-
 
−
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
 
−
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
−
|}
 
−
{{TOC limit|limit=3}}
 
−
=High dose therapy conditioning regimens, all lines of therapy=
 
−
==BCNU/TT {{#subobject:a7b7ae|Regimen=1}}==
 
−
BCNU/TT: '''<u>BCNU</u>''' (Carmustine), '''<u>T</u>'''hio'''<u>T</u>'''epa
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1 {{#subobject:81ede7|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2006.06.2117 Illerhaus et al. 2006]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=81ede7 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 400 mg/m<sup>2</sup> IV once on day 50
 
−
*[[Thiotepa (Thioplex)]] 5 mg/kg (route not specified) once per day on days 51 & 52
 
−
====Supportive therapy====
 
−
*[[:Category:Granulocyte_colony-stimulating_factors|Granulocyte colony-stimulating factor]] starting on day 61, continued until WBC greater than 1 x 10<sup>9</sup>/L for 3 days
 
−
*"Standard supportive measures were taken according to institutional guidelines."
 
−
'''Stem cells re-infused on day 56'''
 
−
</div>
 
−
<section end=81ede7 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2 {{#subobject:769950|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.haematologica.org/content/93/1/147.long Illerhaus et al. 2008]
 
−
| style="background-color:#ffffbe" |Pilot, <20 pts
 
−
|-
 
−
|}
 
−
<section begin=769950 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 400 mg/m<sup>2</sup> IV once on day 1
 
−
*[[Thiotepa (Thioplex)]] 5 mg/kg (route not specified) twice per day on days 2 & 3
 
−
'''Stem cells re-infused on day 7'''
 
−
</div>
 
−
<section end=769950 />
 
−
</div>
 
−
===References===
 
−
<!-- Presented in part at the 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 10-13, 2005. -->
 
−
# Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006 Aug 20;24(24):3865-70. Epub 2006 Jul 24. [https://doi.org/10.1200/jco.2006.06.2117 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16864853 PubMed]
 
−
# Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008 Jan;93(1):147-8. [http://www.haematologica.org/content/93/1/147.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18166803 PubMed]
 
−
==BEAC {{#subobject:60921c|Regimen=1}}==
 
−
BEAC: '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>C</u>'''yclophosphamide
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1 {{#subobject:1a6845|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556606/ Geisler et al. 2008 (NLG MCL2)]
 
−
|style="background-color:#91cf61"|Phase 2
 
−
|-
 
−
|}
 
−
<section begin=1a6845 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day 1
 
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV twice per day on days 2 to 5
 
−
*[[Cytarabine (Ara-C)]] 400 mg/m<sup>2</sup> IV once per day on days 2 to 5
 
−
*[[Cyclophosphamide (Cytoxan)]] 1500 mg/m<sup>2</sup> IV once per day on days 2 to 5
 
−
</div>
 
−
<section end=1a6845 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2 {{#subobject:728b1c|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJM199512073332305 Philip et al. 1995 (PARMA)]
 
−
|1987-1994
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|[[Diffuse_large_B-cell_lymphoma#DHAP|DHAP]] x 4
 
−
| style="background-color:#91cf60" |Seems to have superior OS
 
−
|-
 
−
|}
 
−
<section begin=728b1c />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV over 30 to 60 minutes once on day 1
 
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over 30 to 60 minutes twice per day on days 2 to 5
 
−
*[[Cytarabine (Ara-C)]] 100 mg/m<sup>2</sup> IV over 30 minutes twice per day on days 2 to 5
 
−
*[[Cyclophosphamide (Cytoxan)]] 35 mg/kg IV over 60 minutes once per day on days 2 to 5
 
−
====Supportive therapy====
 
−
*[[Mesna (Mesnex)]] 8.3 mg/kg IV over 30 minutes every 4 hours on days 2 to 5 (optional)
 
−
'''Stem cells re-infused on day 7 (48 hours after last dose of etoposide)'''
 
−
</div>
 
−
<section end=728b1c />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #3 {{#subobject:a5ff49|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.bloodjournal.org/content/77/7/1587.long Philip et al. 1991 (Parma)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=a5ff49 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV over 30 minutes once on day -13
 
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV twice per day on days -12 to -7
 
−
*[[Cytarabine (Ara-C)]] 100 mg/m<sup>2</sup> IV twice per day on days -12 to -9
 
−
*[[Cyclophosphamide (Cytoxan)]] 35 mg/kg IV over 60 minutes once per day on days -12 to -9
 
−
====Supportive therapy====
 
−
*[[Mesna (Mesnex)]] 50 mg/kg IV once per day on days -12 to -9 (optional)
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=a5ff49 />
 
−
</div>
 
−
===References===
 
−
# '''PARMA pilot:''' Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, Spitzer G, Velasquez W, Weisenburger DD, Fernandez-Ranada J, Somers R, Rizzoli V, Harousseau JL, Sotto JJ, Cahn JY, Guilhot F, Biggs J, Sonneveld P, Misset JL, Manna A, Jagannath S, Guglielmi C, Chevreau C, Delmer A, Santini G, Coiffier B. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood. 1991 Apr 1;77(7):1587-92. [http://www.bloodjournal.org/content/77/7/1587.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/2009374 PubMed]
 
−
# '''PARMA:''' Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995 Dec 7;333(23):1540-5. [https://doi.org/10.1056/NEJM199512073332305 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/7477169 PubMed]
 
−
# '''Retrospective:''' Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008 Jan;87(1):43-8. Epub 2007 Aug 21. [https://doi.org/10.1007/s00277-007-0360-0 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/17710401 PubMed]
 
−
# '''NLG MCL2:''' Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008 Oct 1;112(7):2687-93. Epub 2008 Jul 14. [http://www.bloodjournal.org/content/112/7/2687.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556606/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18625886 PubMed]
 
−
==BEAM {{#subobject:1e26e2|Regimen=1}}==
 
−
BEAM: '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1, 300/100q12/100q12/140 with 24-hour rest {{#subobject:13246c|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000843/ Alvarnas et al. 2016 (BMT CTN 0803/AMC 071)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=13246c />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -6
 
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV every 12 hours on days -5 to -2 (total dose: 800 mg/m<sup>2</sup>)
 
−
*[[Cytarabine (Ara-C)]] 100 mg/m<sup>2</sup> IV every 12 hours on days -5 to -2 (total dose: 800 mg/m<sup>2</sup>)
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -1
 
−
</div>
 
−
<section end=13246c />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2, 300/100q12/100q12/140 with 48-hour rest {{#subobject:f28f87|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1111/j.1365-2141.2008.07498.x Van 't Veer et al. 2008 (HOVON 45)]
 
−
|style="background-color:#91cf61"|Phase 2
 
−
|-
 
−
|}
 
−
<section begin=f28f87 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -7
 
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV every 12 hours on days -6 to -3 (total dose: 800 mg/m<sup>2</sup>)
 
−
*[[Cytarabine (Ara-C)]] 100 mg/m<sup>2</sup> IV every 12 hours on days -6 to -3 (total dose: 800 mg/m<sup>2</sup>)
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -2
 
−
</div>
 
−
<section end=f28f87 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #3, 300/100q12/200/140 {{#subobject:76416d|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJM198706113162401 Philip et al. 1987]
 
−
|style="background-color:#91cf61"|Non-randomized
 
−
|-
 
−
|}
 
−
''Paper did not specify which day peripheral blood stem cells were administered. This trial is of important historic interest because it indicated that patients with less than a partial response did worse than those with PR or better.''
 
−
<section begin=76416d />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day 1
 
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV over 60 minutes every 12 hours on days 2 to 5 (total dose: 800 mg/m<sup>2</sup>)
 
−
*[[Cytarabine (Ara-C)]] 200 mg/m<sup>2</sup> IV once per day on days 2 to 5
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV over 5 minutes once on day 6
 
−
</div>
 
−
<section end=76416d />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #4, 300/100q12/200q12/140 {{#subobject:16f7a3|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2003.05.024 Abrey et al. 2003]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|[http://www.bloodjournal.org/content/107/12/4623.long Stewart et al. 2006]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2011.40.2719 d'Amore et al. 2012 (NLG-T-01)]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|-
 
−
|}
 
−
<section begin=16f7a3 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -6
 
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV every 12 hours on days -5 to -2 (total dose: 800 mg/m<sup>2</sup>)
 
−
*[[Cytarabine (Ara-C)]] 200 mg/m<sup>2</sup> IV every 12 hours on days -5 to -2 (total dose: 1600 mg/m<sup>2</sup>)
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -1
 
−
====Supportive therapy====
 
−
*(described in some publications)
 
−
*Patients less than 70 kg: [[Filgrastim (Neupogen)]] 300 mcg SC once per day, starting on day +7 after stem cell transplant
 
−
*Patients greater than 70 kg (reference did not clarify which dosage to use for patients who are exactly 70 kg): [[Filgrastim (Neupogen)]] 480 mcg SC once per day, starting on day +7 after stem cell transplant
 
−
*[[Trimethoprim-Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO twice per day on Monday and Thursdays, until 6 months after BEAM
 
−
''While ANC less than 500/uL:''
 
−
*[[Ciprofloxacin (Cipro)]] 500 mg PO twice per day
 
−
*Antifungal prophylaxis with one of the following:
 
−
**[[Fluconazole (Diflucan)]] 100 mg PO once per day
 
−
**[[Mycostatin (Nystatin)]] 500,000 units swish & swallow four times per day
 
−
*[[Acyclovir (Zovirax)]] 400 mg PO three times per day
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=16f7a3 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #5, 300/100q12/400/140 {{#subobject:2821aa|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556606/ Geisler et al. 2008 (NLG MCL2)]
 
−
|style="background-color:#91cf61"|Phase 2
 
−
|-
 
−
|}
 
−
''Paper did not specify which day peripheral blood stem cells were administered.''
 
−
<section begin=2821aa />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day 1
 
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV twice per day on days 2 to 5 (total dose: 800 mg/m<sup>2</sup>)
 
−
*[[Cytarabine (Ara-C)]] 400 mg/m<sup>2</sup> IV once per day on days 2 to 5
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day 6
 
−
</div>
 
−
<section end=2821aa />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #6, 300/150q12/200q12/140 {{#subobject:5e3c75|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1093/annonc/mdi248 Josting et al. 2005]
 
−
|NR
 
−
| style="background-color:#91cf61" |Phase 2
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|[https://doi.org/10.1016/S0140-6736(02)08938-9 Schmitz et al. 2002 (GHSG HD-R1)]
 
−
|1993-1997
 
−
| style="background-color:#1a9851" |Randomized (E-esc)
 
−
|[[Hodgkin_lymphoma#DexaBEAM|DexaBEAM]]
 
−
| style="background-color:#91cf60" |Seems to have superior FFTF
 
−
|-
 
−
|}
 
−
''Note: Josting et al. 2005 did not specify which day peripheral blood stem cells were administered.''
 
−
<section begin=5e3c75 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -7
 
−
*[[Etoposide (Vepesid)]] 150 mg/m<sup>2</sup> IV every 12 hours on days -7 to -4 (total dose: 1200 mg/m<sup>2</sup>)
 
−
*[[Cytarabine (Ara-C)]] 200 mg/m<sup>2</sup> IV every 12 hours on days -7 to -4 (total dose: 1600 mg/m<sup>2</sup>)
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -3
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=5e3c75 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #7, 300/200/100q12/140 {{#subobject:bbc83f|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1038/sj.bmt.1705452 Colombat et al. 2006]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
''Paper did not specify which day peripheral blood stem cells were administered.''
 
−
<section begin=bbc83f />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day 1
 
−
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days 2 to 5
 
−
*[[Cytarabine (Ara-C)]] 100 mg/m<sup>2</sup> IV every 12 hours on days 2 to 5 (total dose: 800 mg/m<sup>2</sup>)
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day 6
 
−
</div>
 
−
<section end=bbc83f />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #8, 300/200/200/140 {{#subobject:c92668|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/ Gisselbrecht et al. 2010 (CORAL)]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|-
 
−
|}
 
−
<section begin=c92668 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -6
 
−
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days -5 to -2
 
−
*[[Cytarabine (Ara-C)]] 200 mg/m<sup>2</sup> IV once per day on days -5 to -2
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -1
 
−
</div>
 
−
<section end=c92668 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #9, 300/200/200q12/140 with 24 hour rest {{#subobject:fa5ca4|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1002/cncr.27418 Shimoni et al. 2012 (SHEBA-07-4466-AN-CTIL)]
 
−
|NR
 
−
| style="background-color:#1a9851" |Randomized Phase 2 (C)
 
−
|[[#Z-BEAM|Z-BEAM]]
 
−
| style="background-color:#fc8d59" |Seems to have inferior OS
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.2016.69.0198 van Imhoff et al. 2016 (ORCHARRD)]
 
−
|NR
 
−
| style="background-color:#91cf61" |Non-randomized portion of RCT
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|}
 
−
<section begin=fa5ca4 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -6
 
−
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days -5 to -2
 
−
*[[Cytarabine (Ara-C)]] 200 mg/m<sup>2</sup> IV every 12 hours on days -5 to -2 (total dose: 1600 mg/m<sup>2</sup>)
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -1
 
−
====Supportive therapy====
 
−
*Variously described
 
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day +4 "until engraftment"
 
−
*[[Valacyclovir (Valtrex)]] (dose not specified) for one month
 
−
*[[Trimethoprim-Sulfamethoxazole (Bactrim DS)]] (dose/frequency not specified) for six months
 
−
</div>
 
−
<section end=fa5ca4 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #10, 300/200/200q12/140 with 48 hour rest {{#subobject:fa5ca6|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1182/blood.2020008825 Schmitz et al. 2021 (MYS-07-HMO-CTIL)]
 
−
|2011-2014
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[Allogeneic_HSCT#Fludarabine.2C_Busulfan.2C_Cyclophosphamide|Fludarabine, Busulfan, Cyclophosphamide, then allo HSCT]]
 
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS36
 
−
|-
 
−
|}
 
−
<section begin=fa5ca6 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -7
 
−
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days -6 to -3
 
−
*[[Cytarabine (Ara-C)]] 200 mg/m<sup>2</sup> IV every 12 hours on days -6 to -3 (total dose: 1600 mg/m<sup>2</sup>)
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -2
 
−
</div>
 
−
<section end=fa5ca6 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #11, 300/200q12/200q12/140 {{#subobject:75447a|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.haematologica.org/content/88/5/522.long Zinzani et al. 2003]
 
−
| style="background-color:#ffffbe" |Retrospective
 
−
|-
 
−
|}
 
−
<section begin=75447a />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -7
 
−
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV twice per day on days -6 to -3 (total dose: 1600 mg/m<sup>2</sup>)
 
−
*[[Cytarabine (Ara-C)]] 200 mg/m<sup>2</sup> IV twice per day on days -6 to -3 (total dose: 1600 mg/m<sup>2</sup>)
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -2
 
−
</div>
 
−
<section end=75447a />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #12, 300/200/400/140 {{#subobject:d7b00a|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1007/s00277-007-0360-0 Jo et al. 2008]
 
−
| style="background-color:#ffffbe" |Retrospective
 
−
|-
 
−
|}
 
−
<section begin=d7b00a />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -6
 
−
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days -5 to -2
 
−
*[[Cytarabine (Ara-C)]] 400 mg/m<sup>2</sup> IV once per day on days -5 to -2
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -1
 
−
====Supportive therapy====
 
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day +1, continued until there are 3 consecutive days with ANC at least 1000/uL
 
−
*Prophylaxis against opportunistic infections and management of febrile neutropenia per "active protocols"
 
−
</div>
 
−
<section end=d7b00a />
 
−
</div>
 
−
===References===
 
−
# Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M, Laporte JP, Maraninchi D, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987 Jun 11;316(24):1493-8. [https://doi.org/10.1056/NEJM198706113162401 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/3295541 PubMed]
 
−
# '''GHSG HD-R1:''' Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Müller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V; German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002 Jun 15;359(9323):2065-71. [https://doi.org/10.1016/S0140-6736(02)08938-9 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12086759 PubMed]
 
−
# '''Retrospective:''' Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, de Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Giudice V, Zompatori M, Stefoni V, Alinari L, Musuraca G, Bassi S, Conte R, Pileri S, Tura S, Baccarani M. High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience. Haematologica. 2003 May;88(5):522-8. [http://www.haematologica.org/content/88/5/522.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12745271 PubMed]
 
−
# Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6. [https://doi.org/10.1200/jco.2003.05.024 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/14615443 PubMed]
 
−
# '''Retrospective:''' Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, De Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Guidice V, Zompatori M, Stefoni V, Alinari L, Musuraca G, Marchi E, Bassi S, Conte R, Pileri S, Tura S, Baccarani M. High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma. 2004 Feb;45(2):321-6. [https://pubmed.ncbi.nlm.nih.gov/15101718 PubMed]
 
−
# Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dörken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol. 2005 Aug;16(8):1359-65. Epub 2005 Jun 6. [https://doi.org/10.1093/annonc/mdi248 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/15939712 PubMed]
 
−
# Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L, Morris DG, Jones A, Brown C, Russell JA. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2006 Jun 15;107(12):4623-7. Epub 2006 Feb 7. [http://www.bloodjournal.org/content/107/12/4623.long link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/16467197 PubMed] content property of [http://hemonc.org HemOnc.org]
 
−
# Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T; GOELAMS. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. [https://doi.org/10.1038/sj.bmt.1705452 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16951691 PubMed]
 
−
# '''Retrospective:''' Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008 Jan;87(1):43-8. Epub 2007 Aug 21. [https://doi.org/10.1007/s00277-007-0360-0 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/17710401 PubMed]
 
−
# '''NLG MCL2:''' Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008 Oct 1;112(7):2687-93. Epub 2008 Jul 14. [http://www.bloodjournal.org/content/112/7/2687.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556606/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18625886 PubMed] ISRCTN87866680
 
−
# '''HOVON 45:''' Van 't Veer MB, de Jong D, MacKenzie M, Kluin-Nelemans HC, van Oers MH, Zijlstra J, Hagenbeek A, van Putten WL. High-dose Ara-C and BEAM with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol. 2009 Feb;144(4):524-30. Epub 2008 Nov 26. [https://doi.org/10.1111/j.1365-2141.2008.07498.x link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19036081 PubMed]
 
−
<!-- Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 51st Annual Meeting of the American Society of Hematology, December 5-8, 2009, New Orleans, LA. -->
 
−
# '''CORAL:''' Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 Sep 20;28(27):4184-90. Epub 2010 Jul 26. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896. [https://doi.org/10.1200/jco.2010.28.1618 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20660832 PubMed] NCT00137995
 
−
# '''SHEBA-07-4466-AN-CTIL:''' Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012 Oct 1;118(19):4706-14. Epub 2012 Jan 17. [https://doi.org/10.1002/cncr.27418 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22252613 PubMed] NCT00491491
 
−
<!-- Presented orally in part at the 48th Annual Meeting of the American Society of Hematology, Orlando, FL, December 9-12, 2006; 14th Annual Meeting of the European Hematology Association, Berlin, Germany, June 4-7, 2009; 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 15-18, 2011; and American Society of Hematology Annual Meeting, San Diego, CA, December 10-13, 2011. -->
 
−
# '''NLG-T-01:''' d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 Sep 1;30(25):3093-9. Epub 2012 Jul 30. [https://doi.org/10.1200/jco.2011.40.2719 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22851556 PubMed] NCT00791947
 
−
# '''GELTAMO-2006:''' Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol. 2014 Nov;167(3):327-36. Epub 2014 Jul 28. [https://doi.org/10.1111/bjh.13036 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25066542 PubMed] NCT013611091
 
−
# '''BMT CTN 0803/AMC 071:''' Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE Jr, Thompson J, Horowitz MM, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder R. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016 Aug 25;128(8):1050-8. Epub 2016 Jun 13. [http://www.bloodjournal.org/content/128/8/1050.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000843/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27297790 PubMed] NCT01141712
 
−
# '''ORCHARRD:''' van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MD, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017 Feb 10;35(5):544-51. Epub 2016 Dec 28. [https://doi.org/10.1200/JCO.2016.69.0198 link to original article] [https://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198/suppl_file/ds_2016.690198.pdf link to data supplement] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/28029326 PubMed] NCT01014208
 
−
# '''MYS-07-HMO-CTIL:''' Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner E, Wilhelm M, Sanhes L, Lamy T, de Leval L, Rosenwald A, Roussel M, Kroschinsky F, Lindemann W, Dreger P, Viardot A, Milpied N, Gisselbrecht C, Wulf G, Gyan E, Gaulard P, Bay JO, Glass B, Poeschel V, Damaj G, Sibon D, Delmer A, Bilger K, Banos A, Haenel M, Dreyling M, Metzner B, Keller U, Braulke F, Friedrichs B, Nickelsen M, Altmann B, Tournilhac O. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021 May 13;137(19):2646-2656. [https://doi.org/10.1182/blood.2020008825 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/33512419/ PubMed] NCT00984412
 
−
==BeEAM {{#subobject:dee72f|Regimen=1}}==
 
−
BeEAM: '''<u>Be</u>'''ndamustine, '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:81ff2e|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.bloodjournal.org/content/118/12/3419.long Visani et al. 2011]
 
−
| style="background-color:#91cf61" |Phase 1/2
 
−
|-
 
−
|}
 
−
<section begin=81ff2e />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Bendamustine]] 200 mg/m<sup>2</sup> IV once per day on days -7 & -6
 
−
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days -5 to -2
 
−
*[[Cytarabine (Ara-C)]] 400 mg/m<sup>2</sup> IV once per day on days -5 to -2
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -1
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=81ff2e />
 
−
</div>
 
−
===References===
 
−
# Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011 Sep 22;118(12):3419-25. Epub 2011 Aug 3. [http://www.bloodjournal.org/content/118/12/3419.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21816830 PubMed] EudraCT 2008-002736-15
 
−
==Bortezomib & Melphalan {{#subobject:9c28bc|Regimen=1}}==
 
−
Bor-HDM: '''<u>Bor</u>'''tezomib, '''<u>H</u>'''igh '''<u>D</u>'''ose '''<u>M</u>'''elphalan
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1, HDM 140 mg/m<sup>2</sup> {{#subobject:c0ec02|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.bbmt.org/article/S1083-8791(15)00230-X Sanchorawala et al. 2015 (X05292)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=c0ec02 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> IV once per day on days -6, -3, +1, +4
 
−
====Chemotherapy====
 
−
*[[Melphalan (Alkeran)]] 70 mg/m<sup>2</sup> IV once per day on days -2 & -1
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=c0ec02 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2, HDM 200 mg/m<sup>2</sup> {{#subobject:0bfd33|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.bloodjournal.org/content/115/1/32.long Roussel et al. 2009]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|[http://www.bbmt.org/article/S1083-8791(15)00230-X Sanchorawala et al. 2015 (X05292)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=0bfd33 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> IV once per day on days -6, -3, +1, +4
 
−
====Chemotherapy====
 
−
*[[Melphalan (Alkeran)]] 100 mg/m<sup>2</sup> IV once per day on days -2 & -1
 
−
**Roussel et al. 2009 gave as a single 200 mg/m<sup>2</sup> dose on day -2
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=0bfd33 />
 
−
</div>
 
−
===References===
 
−
# Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D, Hulin C, Fruchart C, Marit G, Pégourié B, Lenain P, Araujo C, Kolb B, Randriamalala E, Royer B, Stoppa AM, Dib M, Dorvaux V, Garderet L, Mathiot C, Avet-Loiseau H, Harousseau JL, Attal M; Intergroupe Francophone du Myélome. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood. 2010 Jan 7;115(1):32-7. Epub 2009 Nov 2. [http://www.bloodjournal.org/content/115/1/32.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19884643 PubMed] NCT00642395
 
−
# '''X05292:''' Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC. Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: Results of a prospective clinical trial. Biol Blood Marrow Transplant. 2015 Aug;21(8):1445-51. Epub 2015 Apr 6. [http://www.bbmt.org/article/S1083-8791(15)00230-X link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25858810 PubMed] NCT01083316
 
−
==Busulfan & Cyclophosphamide {{#subobject:9acbe9|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1, 16/120 {{#subobject:6ccf66|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[http://www.bloodjournal.org/content/118/23/6037.long Vellenga et al. 2011 (HOVON-SAKK AML-29/AML-42)]
 
−
|1995-2006
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|[[Acute_myeloid_leukemia#Etoposide_.26_Mitoxantrone|Etoposide & Mitoxantrone]]
 
−
| style="background-color:#d9ef8b" |Might have superior RFS
 
−
|-
 
−
|}
 
−
<section begin=6ccf66 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Busulfan (Myleran)]] 4 mg/kg PO (frequency not specified) on days -7 to -4
 
−
*[[Cyclophosphamide (Cytoxan)]] 60 mg/kg IV once per day on days -3 & -2
 
−
</div>
 
−
<section end=6ccf66 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2, 16/200 {{#subobject:5d4efb|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJM199605303342203 Ravindranath et al. 1996]
 
−
|1988-1993
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|Intensive chemotherapy
 
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS36
 
−
|-
 
−
|}
 
−
<section begin=5d4efb />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Busulfan (Myleran)]] 1 mg/kg PO every 6 hours on days -9 to -6
 
−
*[[Cyclophosphamide (Cytoxan)]] 50 mg/kg IV once per day on days -5 to -2
 
−
</div>
 
−
<section end=5d4efb />
 
−
</div>
 
−
===References===
 
−
# Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, Carroll A, Inoue S, Camitta B, Weinstein HJ; Pediatric Oncology Group. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med. 1996 May 30;334(22):1428-34. [https://doi.org/10.1056/NEJM199605303342203 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/8618581 PubMed]
 
−
# '''HOVON-SAKK AML-29/AML-42:''' Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ, Huijgens PC, Maertens J, Gratwohl A, Schaafsma R, Schanz U, Graux C, Schouten HC, Ferrant A, Bargetzi M, Fey MF, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group; Swiss Group for Clinical Cancer Research. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood. 2011 Dec 1;118(23):6037-42. Epub 2011 Sep 27. [http://www.bloodjournal.org/content/118/23/6037.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21951683 PubMed]
 
−
==Busulfan & Melphalan {{#subobject:484436|Regimen=1}}==
 
−
BuMel: '''<u>Bu</u>'''sulfan & '''<u>Mel</u>'''phalan
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1, PO busulfan (12 mg/kg) {{#subobject:c5fc8f|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.bloodjournal.org/content/121/16/3095.long Yanada et al. 2013 (JALSG APL205R)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
''This regimen was evaluated in the setting of relapsed [[acute promyelocytic leukemia]].''
 
−
<section begin=c5fc8f />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Busulfan (Myleran)]] 1 mg/kg PO every 6 hours on days -6 to -4 (total dose of 12 mg/kg)
 
−
*[[Melphalan (Alkeran)]] 70 mg/m<sup>2</sup> IV bolus once per day on days -3 & -2
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=c5fc8f />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2, PO busulfan (16 mg/kg), mel 140 mg/m<sup>2</sup> {{#subobject:75d2e0|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1038/sj.bmt.1700992 Atra et al. 1997]
 
−
|NR
 
−
| style="background-color:#ffffbe" |Phase 2, <20 pts
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209090/ Whelan et al. 2018 (R2Loc)]
 
−
|2000-2015
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|[[Ewing_sarcoma#VAI|VAI]]
 
−
| style="background-color:#91cf60" |Seems to have superior OS
 
−
|-
 
−
|}
 
−
''This regimen was evaluated in the setting of poor risk [[Ewing sarcoma]].''
 
−
<section begin=75d2e0 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Busulfan (Myleran)]] 1 mg/kg PO every 6 hours on days -5 to -2 (total dose of 16 mg/kg)
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -1
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=75d2e0 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #3, PO busulfan (16 mg/kg), mel 160 mg/m<sup>2</sup> {{#subobject:75d2e1|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1038/sj.bmt.1700992 Atra et al. 1997]
 
−
|NR
 
−
| style="background-color:#ffffbe" |Phase 2, <20 pts
 
−
|-
 
−
|}
 
−
''This regimen was evaluated in the setting of poor risk [[Ewing sarcoma]].''
 
−
<section begin=75d2e1 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Busulfan (Myleran)]] 1 mg/kg PO every 6 hours on days -5 to -2 (total dose of 16 mg/kg)
 
−
*[[Melphalan (Alkeran)]] 160 mg/m<sup>2</sup> IV once on day -1
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=75d2e1 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #4, IV busulfan {{#subobject:a61951|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2003.04.106 Strauss et al. 2003]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
''This regimen was evaluated in the setting of metastatic [[Ewing sarcoma]]. Note that melphalan is reported as given on day 2 (not day -2) in the original reference but this is surely an error.''
 
−
<section begin=a61951 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Busulfan (Myleran)]] 150 mg/m<sup>2</sup> IV once per day on days -6 to -3
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -2
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=a61951 />
 
−
</div>
 
−
===References===
 
−
# Atra A, Whelan JS, Calvagna V, Shankar AG, Ashley S, Shepherd V, Souhami RL, Pinkerton CR. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant. 1997 Nov;20(10):843-6. [https://doi.org/10.1038/sj.bmt.1700992 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9404924 PubMed]
 
−
# Strauss SJ, McTiernan A, Driver D, Hall-Craggs M, Sandison A, Cassoni AM, Kilby A, Michelagnoli M, Pringle J, Cobb J, Briggs T, Cannon S, Witt J, Whelan JS. Single center experience of a new intensive induction therapy for Ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties. J Clin Oncol. 2003 Aug 1;21(15):2974-81. [https://doi.org/10.1200/jco.2003.04.106 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12885818 PubMed]
 
−
# '''JALSG APL205R:''' Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N; Japan Adult Leukemia Study Group. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 Apr 18;121(16):3095-102. Epub 2013 Feb 14. [http://www.bloodjournal.org/content/121/16/3095.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23412094 PubMed] NCT01908621
 
−
# '''R2Loc:''' Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, Hawkins DS, Amler S, Bauer S, Bielack S, Blay JY, Burdach S, Castex MP, Dilloo D, Eggert A, Gelderblom H, Gentet JC, Hartmann W, Hassenpflug WA, Hjorth L, Jimenez M, Klingebiel T, Kontny U, Kruseova J, Ladenstein R, Laurence V, Lervat C, Marec-Berard P, Marreaud S, Michon J, Morland B, Paulussen M, Ranft A, Reichardt P, van den Berg H, Wheatley K, Judson I, Lewis I, Craft A, Juergens H, Oberlin O; Euro-EWING-99 and EWING-2008 Investigators. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-EWING99 and Ewing-2008. J Clin Oncol. 2018 Nov 1;36(31):3110-9. Epub 2018 Sep 6. [https://doi.org/10.1200/JCO.2018.78.2516 link to original article] '''contains dosing details in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209090/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30188789 PubMed] NCT00020566
 
−
==Bu/TT {{#subobject:e04a91|Regimen=1}}==
 
−
Bu/TT: '''<u>Bu</u>'''sulfan, '''<u>T</u>'''hio'''<u>T</u>'''epa
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:df1bb4|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1093/annonc/mdl458 Montemurro et al. 2007 (OSHO-53)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=df1bb4 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Busulfan (Myleran)]] 4 mg/kg PO four times per day on days -8 to -5
 
−
*[[Thiotepa (Thioplex)]] 5 mg/kg IV once per day on days -4 & -3
 
−
</div>
 
−
<section end=df1bb4 />
 
−
</div>
 
−
===References===
 
−
# '''OSHO-53:''' Montemurro M, Kiefer T, Schüler F, Al-Ali HK, Wolf HH, Herbst R, Haas A, Helke K, Theilig A, Lotze C, Hirt C, Niederwieser D, Schwenke M, Krüger WH, Dölken G. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol. 2007 Apr;18(4):665-71. Epub 2006 Dec 21. [https://doi.org/10.1093/annonc/mdl458 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17185743 PubMed]
 
−
==Bu/TT/Cy {{#subobject:e04a91|Regimen=1}}==
 
−
Bu/TT/Cy: '''<u>Bu</u>'''sulfan, '''<u>T</u>'''hio'''<u>T</u>'''epa, '''<u>Cy</u>'''clophosphamide
 
−
<br>TBC: '''<u>T</u>'''hiotepa, '''<u>B</u>'''usulfan, , '''<u>Cy</u>'''clophosphamide
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:df1bb4|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342354/ Omuro et al. 2015 (MSK 04-129)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
''Primary indication: [[CNS lymphoma|primary CNS lymphoma (PCNSL)]]''
 
−
<section begin=df1bb4 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Thiotepa (Thioplex)]] 250 mg/m<sup>2</sup> IV once per day on days -9, -8, and -7
 
−
*[[Busulfan (Myleran)]] 3.2 mg/kg IV once per day on days -6, -5, and -4
 
−
*[[Cyclophosphamide (Cytoxan)]] 60 mg/kg IV once per day on days -3 and -2
 
−
</div>
 
−
<section end=df1bb4 />
 
−
</div>
 
−
===References===
 
−
# '''MSK 04-129:''' Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015 Feb 26;125(9):1403-10. Epub 2015 Jan 7. [http://www.bloodjournal.org/content/125/9/1403 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342354/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25568347 PubMed] NCT00596154
 
−
# '''Retrospective:''' DeFilipp Z, Li S, El-Jawahri A, Armand P, Nayak L, Wang N, Batchelor TT, Chen YB. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer. 2017 Aug 15;123(16):3073-3079. Epub 2017 Apr 3. [https://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30695 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28369839 PubMed]
 
−
==CBV {{#subobject:935235|Regimen=1}}==
 
−
CBV: '''<u>C</u>'''yclophosphamide, '''<u>B</u>'''iCNU (Carmustine), '''<u>V</u>'''P-16 (Etoposide)
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1, 100/300/60, some BSA-based {{#subobject:6fc278|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985418/ Stiff et al. 2013 (SWOG S9704)]
 
−
|1999-2007
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|[[#R-CHOP|R-CHOP]] x 8
 
−
| style="background-color:#1a9850" |Superior PFS
 
−
|-
 
−
|}
 
−
<section begin=6fc278 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 100 mg/kg (IBW) IV once on day -2
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -6
 
−
*[[Etoposide (Vepesid)]] 60 mg/kg (IBW) IV once on day -4
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=6fc278 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2, 100/15/60, all weight-based {{#subobject:35a696|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.1998.16.1.48 Stiff et al. 1998]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793032/ Damon et al. 2009 (CALGB 59909)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=35a696 />
 
−
''Note: Stiff et al. 1998 based BCNU dosing on ideal body weight, whereas CALGB 59909 capped based on BSA, as described below.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 100 mg/kg IV over 2 hours once on day -2
 
−
*[[Carmustine (BCNU)]] 15 mg/kg (maximum dose of 550 mg/m<sup>2</sup>) IV over 60 minutes once on day -6
 
−
*[[Etoposide (Vepesid)]] 60 mg/kg IV over 4 hours once on day -4
 
−
====Supportive therapy====
 
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day +4, to continue until ANC greater than 5000/uL once or greater than 1500/uL twice
 
−
*[[Levofloxacin (Levaquin)]] 500 mg PO once per day, starting on day +2, to continue until ANC at least 500/uL
 
−
*[[Fluconazole (Diflucan)]] 200 mg PO once per day, starting on day +1, to continue until ANC at least 500/uL
 
−
*[[Acyclovir (Zovirax)]] 200 mg PO three times per day, starting on day -2, to continue until 1 year after HSCT
 
−
*[[Trimethoprim-Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO twice per day on Saturday and Sunday, to continue until 3 months after HSCT
 
−
=====Additional considerations=====
 
−
If any patient appeared to be experiencing carmustine-induced pneumonitis:
 
−
*[[Prednisone (Sterapred)]] 0.5 mg/kg PO twice per day x 2 weeks, then tapered over 4 weeks
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=35a696 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
  
−
===Regimen variant #3, 1500/300/250, all BSA-based {{#subobject:1ba6d|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.haematologica.org/content/88/5/522.long Zinzani et al. 2003]
 
−
| style="background-color:#ffffbe" |Retrospective
 
−
|-
 
−
|}
 
−
<section begin=1ba6d />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 1500 mg/m<sup>2</sup> IV once per day on days -6 to -3
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -6
 
−
*[[Etoposide (Vepesid)]] 250 mg/m<sup>2</sup> IV once per day on days -6 to -4
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=1ba6d />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #4, 1800/600/400 {{#subobject:cf6828|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.bloodjournal.org/content/83/5/1193.long Reece et al. 1994]
 
−
| style="background-color:#ffffbe" |Phase 2, <20 pts
 
−
|-
 
−
|}
 
−
<section begin=cf6828 />
 
−
''Note: the lower of IBW or ABW was used in the dosing calculations.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 1800 mg/m<sup>2</sup> IV over 2 hours once per day on days -7 to -4
 
−
*[[Carmustine (BCNU)]] 600 mg/m<sup>2</sup> IV once on day -3
 
−
*[[Etoposide (Vepesid)]] 400 mg/m<sup>2</sup> IV over 60 minutes every 12 hours on days -7 to -5
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=cf6828 />
 
−
</div>
 
−
 
−
===References===
 
−
# Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nantel SH, O'Reilly S, Shepherd JD, Sutherland HJ, Voss N, Chan KW, Phillips GL. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood. 1994 Mar 1;83(5):1193-9. [http://www.bloodjournal.org/content/83/5/1193.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/8118023 PubMed]
 
−
# Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI; [[Study_Groups#SWOG|SWOG]]. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. J Clin Oncol. 1998 Jan;16(1):48-55. [https://doi.org/10.1200/jco.1998.16.1.48 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9440722 PubMed]
 
−
# '''Retrospective:''' Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, de Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Giudice V, Zompatori M, Stefoni V, Alinari L, Musuraca G, Bassi S, Conte R, Pileri S, Tura S, Baccarani M. High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience. Haematologica. 2003 May;88(5):522-8. [http://www.haematologica.org/content/88/5/522.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12745271 PubMed]
 
−
# '''CALGB 59909:''' Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20;27(36):6101-8. Epub 2009 Nov 16. [https://doi.org/10.1200/jco.2009.22.2554 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793032/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19917845 PubMed] NCT00020943
 
−
# '''SWOG S9704:''' Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013 Oct 31;369(18):1681-90. [https://doi.org/10.1056/NEJMoa1301077 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985418/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24171516 PubMed] NCT00004031
 
−
==CBV-Mx {{#subobject:77feb1|Regimen=1}}==
 
−
CBV-Mx: '''<u>C</u>'''yclophosphamide, '''<u>B</u>'''iCNU (Carmustine), '''<u>V</u>'''P-16 (Etoposide), '''<u>M</u>'''ito'''<u>x</u>'''antrone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:8271c4|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2007.15.5887 Morschhauser et al. 2008 (GELA/SFGM H96)]
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
|-
 
−
|}
 
−
<section begin=8271c4 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 1500 mg/m<sup>2</sup>/day IV on days -7 to -4
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -4
 
−
*[[Etoposide (Vepesid)]] 250 mg/m<sup>2</sup>/day IV on days -7 to -4
 
−
*[[Mitoxantrone (Novantrone)]] 30 mg/m<sup>2</sup> IV once on day -8
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=8271c4 />
 
−
</div>
 
−
===References===
 
−
# '''GELA/SFGM H96:''' Morschhauser F, Brice P, Fermé C, Diviné M, Salles G, Bouabdallah R, Sebban C, Voillat L, Casasnovas O, Stamatoullas A, Bouabdallah K, André M, Jais JP, Cazals-Hatem D, Gisselbrecht C; GELA; SFGM. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008 Dec 20;26(36):5980-7. Epub 2008 Nov 17. [https://doi.org/10.1200/jco.2007.15.5887 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19018090 PubMed]
 
−
## '''Update:''' Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marçais A, Deau-Fischer B, Bouabdallah R, Sebban C, Salles G, Brice P. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica. 2016 Apr;101(4):474-81. Epub 2015 Dec 31. [http://www.haematologica.org/content/101/4/474 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004408/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26721893 PubMed]
 
−
==CHUT {{#subobject:e9e363|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:392c1c|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://www.nature.com/articles/1705935 Biron et al. 2007 (Pegase 03)]
 
−
|1995-2001
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|[[#Observation_88|No further treatment]]
 
−
| style="background-color:#1a9850" |Superior DFS
 
−
|-
 
−
|}
 
−
''No longer used, but of historical interest.''
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 6000 mg/m<sup>2</sup>
 
−
*[[Thiotepa (Thioplex)]] 800 mg/m<sup>2</sup>
 
−
</div></div>
 
−
===References===
 
−
# '''Pegase 03:''' Biron P, Durand M, Roché H, Delozier T, Battista C, Fargeot P, Spaeth D, Bachelot T, Poiget E, Monnot F, Tanguy ML, Curé H. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant. 2008 Mar;41(6):555-62. Epub 2007 Nov 26. [https://www.nature.com/articles/1705935 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18037940 PubMed] NCT00002870
 
−
==CTCb {{#subobject:02f569|Regimen=1}}==
 
−
CTCb: '''<u>C</u>'''yclophosphamide, '''<u>T</u>'''hiotepa, '''<u>C</u>'''ar'''<u>b</u>'''oplatin
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:3dea9c|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.1990.8.7.1239 Eder et al. 1990]
 
−
|1987-1988
 
−
| style="background-color:#91cf61" |Phase 1/2
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|[https://doi.org/10.1056/NEJM200004133421501 Stadtmauer et al. 2000]
 
−
|1990-1997
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|[[Breast_cancer#CMF_2|CMF]]
 
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
−
|-
 
−
|[https://doi.org/10.1016/S0140-6736(98)01350-6 Rodenhuis et al. 1998]
 
−
|1991-1995
 
−
| style="background-color:#1a9851" |Randomized Phase 2 (E-esc)
 
−
|Standard adjuvant therapy
 
−
| style="background-color:#ffffbf" |Did not meet primary endpoints of DFS/OS
 
−
|-
 
−
|[https://doi.org/10.1056/NEJMoa022794 Rodenhuis et al. 2003 (Dutch National Study)]
 
−
|1993-1999
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|[[Breast_cancer#FEC_2|FEC]] x 5
 
−
| style="background-color:#d9ef8b" |Might have superior RFS
 
−
|-
 
−
|}
 
−
''No longer used, but of historical interest.''
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 6000 mg/m<sup>2</sup>
 
−
*[[Thiotepa (Thioplex)]] 480 mg/m<sup>2</sup>
 
−
*[[Carboplatin (Paraplatin)]] 1600 mg/m<sup>2</sup>
 
−
</div></div>
 
−
===References===
 
−
# Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E 3rd, Antman K. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol. 1990 Jul;8(7):1239-45. [https://doi.org/10.1200/jco.1990.8.7.1239 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2162912 PubMed]
 
−
# Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998 Aug 15;352(9127):515-21. [https://doi.org/10.1016/S0140-6736(98)01350-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9716055 PubMed]
 
−
# Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH; Philadelphia Bone Marrow Transplant Group. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med. 2000 Apr 13;342(15):1069-76. [https://doi.org/10.1056/NEJM200004133421501 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10760307 PubMed]
 
−
# '''Dutch National Study:''' Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EG; Netherlands Working Party on Autologous Transplantation in Solid Tumors. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003 Jul 3;349(1):7-16. [https://doi.org/10.1056/NEJMoa022794 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12840087 PubMed] NCT03087409
 
−
==Cyclophosphamide, Etoposide, TBI {{#subobject:1fcca8|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:a79295|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.1998.16.1.48 Stiff et al. 1998]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=a79295 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 100 mg/kg IV over 1 to 2 hours once on day -2
 
−
*[[Etoposide (Vepesid)]] 60 mg/kg IV over 4 hours once on day -4
 
−
====Radiotherapy====
 
−
*[[External_beam_radiotherapy|Total body irradiation (TBI)]]  with 150 cGy fractions given twice per day (fractions are at least 5 hours apart) x 8 fractions (total dose: 1200 cGy) over 4 days on days -8 to -5, with lung shielding for the final 600 Gy
 
−
**Note: Table 1 of Stiff et al. 1998 lists the dosage of each fraction as being 120 cGy, in contrast to the body text under "treatment regimen" saying each fraction is 150 cGy. It is believed that the 150 cGy dose is correct since 8 fractions of this results in the correct total dose of 1200 cGy.
 
−
====Supportive therapy====
 
−
*[[Diphenhydramine (Benadryl)]] 25 mg (route not specified) once 2 hours before [[Etoposide (Vepesid)]] to prevent allergic reaction
 
−
*[[Hydrocortisone (Cortef)]] 100 mg (route not specified) once 2 hours before [[Etoposide (Vepesid)]] to prevent allergic reaction
 
−
*"Continuous bladder irrigation and vigorous hydration were used" to protect against hemorrhagic cystitis
 
−
</div>
 
−
<section end=a79295 />
 
−
</div>
 
−
===References===
 
−
# Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI; [[Study_Groups#SWOG|SWOG]]. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. J Clin Oncol. 1998 Jan;16(1):48-55. [https://doi.org/10.1200/jco.1998.16.1.48 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9440722 PubMed]
 
−
==Cyclophosphamide & TBI {{#subobject:0a4915|Regimen=1}}==
 
−
Cy/TBI: '''<u>Cy</u>'''clophosphamide & '''<u>T</u>'''otal '''<u>B</u>'''ody '''<u>I</u>'''rradiation
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:a2b2d3|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJM198406143102403 Phillips et al. 1984]
 
−
|1977-1982
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|[https://doi.org/10.1056/NEJM198706113162402 Takvorian et al. 1987]
 
−
|1982-1987
 
−
| style="background-color:#91cf61" |Non-randomized
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.2003.10.023 Schouten et al. 2003 (CUP)]
 
−
|1993-1997
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|[[#CHOP_88|CHOP]] x 3
 
−
| style="background-color:#d9ef8b" |Might have superior OS
 
−
|-
 
−
|[http://www.bloodjournal.org/content/105/7/2677.long Dreyling et al. 2004]
 
−
|1996-2004
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|[[Mantle_cell_lymphoma#Interferon_alfa_monotherapy|Interferon alfa]] maintenance
 
−
| style="background-color:#91cf60" |Seems to have superior PFS
 
−
|-
 
−
|[https://doi.org/10.1038/sj.thj.6200359 Reimer et al. 2004]
 
−
|2000-2002
 
−
| style="background-color:#91cf61" |Phase 2
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|}
 
−
<section begin=a2b2d3 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 60 mg/kg IV once per day on days -3 & -2
 
−
====Radiotherapy====
 
−
*[[External_beam_radiotherapy|Total body irradiation (TBI)]]  1200 cGy in fractions on days –6 to –4 (pulmonary dosage was limited to 800 cGy)
 
−
</div>
 
−
<section end=a2b2d3 />
 
−
</div>
 
−
===References===
 
−
# Phillips GL, Herzig RH, Lazarus HM, Fay JW, Wolff SN, Mill WB, Lin H, Thomas PR, Glasgow GP, Shina DC, Herzig GP. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. N Engl J Med. 1984 Jun 14;310(24):1557-61. [https://doi.org/10.1056/NEJM198406143102403 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6374452 PubMed]
 
−
# Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch P, Tarbell N, Coral F, Daley H, Yeap B, Schlossman SF, Nadler LM. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 1987 Jun 11;316(24):1499-505. [https://doi.org/10.1056/NEJM198706113162402 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3295542 PubMed]
 
−
# '''CUP:''' Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, Doorduijn JK, Sydes MR, Kvalheim G. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003 Nov 1;21(21):3918-27. Epub 2003 Sep 29. [https://doi.org/10.1200/JCO.2003.10.023 link to original article] [https://pubmed.ncbi.nlm.nih.gov/14517188 PubMed]
 
−
# Reimer P, Schertlin T, Rüdiger T, Geissinger E, Roth S, Kunzmann V, Weissinger F, Nerl C, Schmitz N, Müller-Hermelink HK, Wilhelm M. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J. 2004;5(4):304-11. [https://doi.org/10.1038/sj.thj.6200359 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15297846 PubMed]
 
−
## '''Update:''' Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, Engert A, Einsele H, Müller-Hermelink HK, Wilhelm M. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009 Jan 1;27(1):106-13. Epub 2008 Nov 24. [https://doi.org/10.1200/jco.2008.17.4870 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19029417 PubMed]
 
−
# Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. [http://www.bloodjournal.org/content/105/7/2677.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/15591112 PubMed]
 
−
==Etoposide & TBI {{#subobject:9a9f4e|Regimen=1}}==
 
−
Etoposide & TBI: Etoposide & '''<u>T</u>'''otal '''<u>B</u>'''ody '''<u>I</u>'''rradiation
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:1b94c5|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[http://www.bloodjournal.org/content/106/12/3760.long Rowe et al. 2005 (MRC UKALL XII/ECOG E2993)]
 
−
|1993-2003
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|[[Acute_lymphocytic_leukemia#International_ALL_Trial|International ALL Trial]] consolidation, then [[Acute_lymphocytic_leukemia#POMP|POMP]] maintenance
 
−
| style="background-color:#fc8d59" |Seems to have inferior OS
 
−
|-
 
−
|}
 
−
''Note: this is the same preparative regimen used for allogeneic transplant for certain patients; see reference for details. This regimen was evaluated in the treatment of acute lymphoblastic leukemia in CR1.''
 
−
<section begin=1b94c5 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Etoposide (Vepesid)]] 60 mg/kg IV once on day -3
 
−
====Radiotherapy====
 
−
*[[External_beam_radiotherapy|Total body irradiation (TBI)]]  220 cGy twice per day in 6 fractions on days –6 to –4 (total dose: 1320 cGy)
 
−
</div>
 
−
<section end=1b94c5 />
 
−
</div>
 
−
===References===
 
−
# '''MRC UKALL XII/ECOG E2993:''' Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH; ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005 Dec 1;106(12):3760-7. Epub 2005 Aug 16. [http://www.bloodjournal.org/content/106/12/3760.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16105981 PubMed] NCT00002514
 
−
## '''Update:''' Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008 Feb 15;111(4):1827-33. Epub 2007 Nov 29. [http://www.bloodjournal.org/content/111/4/1827.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/18048644 PubMed]
 
−
## '''Update:''' Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan AK, Litzow MR, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009 May 7;113(19):4489-96. Epub 2009 Feb 24. [http://www.bloodjournal.org/content/113/19/4489.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188540/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19244158 PubMed]
 
−
## '''Update:''' Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, Lazarus H, Luger SM, Marks DI, McMillan AK, Moorman AV, Patel B, Paietta E, Tallman MS, Goldstone AH. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014 Feb 6;123(6):843-50. Epub 2013 Nov 25. [http://www.bloodjournal.org/content/123/6/843.full link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916877/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24277073 PubMed]
 
−
==FEAM {{#subobject:0aac6f|Regimen=1}}==
 
−
FEAM: '''<u>F</u>'''otemustine, '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:74d43c|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1038/bmt.2009.318 Musso et al. 2009]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053328/ Musso et al. 2015]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=74d43c />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Fotemustine (Muphoran)]]
 
−
*[[Etoposide (Vepesid)]]
 
−
*[[Cytarabine (Ara-C)]]
 
−
*[[Melphalan (Alkeran)]]
 
−
</div>
 
−
<section end=74d43c />
 
−
</div>
 
−
===References===
 
−
# Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, Di Bartolomeo P, Crescimanno A, Perrone T, Pinto A. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant. 2010 Jul;45(7):1147-53. Epub 2009 Nov 9. [https://doi.org/10.1038/bmt.2009.318 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19898504 PubMed]
 
−
# Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. Br J Haematol. 2016 Jan;172(1):111-21. Epub 2015 Oct 12. [https://doi.org/10.1111/bjh.13803 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053328/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26458240 PubMed]
 
−
==LEED {{#subobject:ee43e6|Regimen=1}}==
 
−
LEED: '''<u>L</u>'''-PAM (Melphalan), '''<u>E</u>'''ndoxan (Cyclophosphamide), '''<u>E</u>'''toposide, '''<u>D</u>'''examethasone
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:47e3df|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.2016.69.0198 van Imhoff et al. 2016 (ORCHARRD)]
 
−
| style="background-color:#91cf61" |Non-randomized portion of RCT
 
−
|-
 
−
|}
 
−
''Note: this protocol does not appear to be commonly used outside of Japan.''
 
−
<section begin=47e3df />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Melphalan (Alkeran)]] 130 mg/m<sup>2</sup> IV once on day -1
 
−
*[[Cyclophosphamide (Cytoxan)]] 60 mg/kg IV once per day on days -4 & -3
 
−
*[[Etoposide (Vepesid)]] 500 mg/m<sup>2</sup> IV once per day on days -4 to -2
 
−
====Glucocorticoid therapy====
 
−
*[[Dexamethasone (Decadron)]] 40 mg IV once per day on days -4 to -1
 
−
</div>
 
−
<section end=47e3df />
 
−
</div>
 
−
===References===
 
−
# '''ORCHARRD:''' van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MD, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017 Feb 10;35(5):544-51. Epub 2016 Dec 28. [https://doi.org/10.1200/JCO.2016.69.0198 link to original article] [https://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198/suppl_file/ds_2016.690198.pdf link to data supplement] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/28029326 PubMed] NCT01014208
 
−
==Melphalan & TBI {{#subobject:94f995|Regimen=1}}==
 
−
Melphalan & TBI: Melphalan & '''<u>T</u>'''otal '''<u>B</u>'''ody '''<u>I</u>'''rradiation
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:ad4db8|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.haematologica.org/content/95/8/1350.full Gressin et al. 2010 (GOELAMS LM1996)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|[http://www.haematologica.org/content/95/8/1350.full Gressin et al. 2010 (GOELAMS LM2001)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=ad4db8 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once (day not specified)
 
−
====Radiotherapy====
 
−
*[[External_beam_radiotherapy|Total body irradiation (TBI)]] : 800 cGy in 4 fractions (days not specified)
 
−
</div>
 
−
<section end=ad4db8 />
 
−
</div>
 
−
===References===
 
−
# '''GOELAMS LM1996:''' Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; GOELAMS. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma: combined results of two prospective phase II trials from the French GOELAMS Group. Haematologica. 2010 Aug;95(8):1350-7. Epub 2010 Mar 10. [http://www.haematologica.org/content/95/8/1350.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913084/ link to PMC article] '''contains partial protocol''' [https://pubmed.ncbi.nlm.nih.gov/20220059 PubMed]
 
−
# '''GOELAMS LM2001:''' Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; GOELAMS. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma: combined results of two prospective phase II trials from the French GOELAMS Group. Haematologica. 2010 Aug;95(8):1350-7. Epub 2010 Mar 10. [http://www.haematologica.org/content/95/8/1350.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913084/ link to PMC article] '''contains partial protocol''' [https://pubmed.ncbi.nlm.nih.gov/20220059 PubMed] NCT00285389
 
−
==Melphalan monotherapy {{#subobject:404662|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:e63043|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://annals.org/article.aspx?articleid=717091 Skinner et al. 2004]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
''Eligibility criteria: Biopsy-proven amyloid disease and at least 1 major organ involved, evidence of plasma cell dyscrasia, no heart failure or arrhythmia that cannot be medically managed, cardiac ejection fraction at least 40%, no pleural effusions, supine systolic blood pressure at least 90 mmHg, O2 saturation at least 95% on room air, lung diffusing capacity at least 50% predicted, SWOG performance status less than or equal to 2 unless due to neuropathy.''
 
−
<section begin=e63043 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Melphalan (Alkeran)]] by the following criteria:
 
−
**Patients who fulfilled all of these criteria--younger than 65 years old, cardiac ejection fraction at least 45%, and at least 2.5 x 10<sup>6</sup> CD34+ cells/kg collected: 100 mg/m<sup>2</sup> IV once per day on days 1 & 2
 
−
**Patients with at least one of these criteria-->65 years old, cardiac ejection fraction 40 to 44%, or with 2 to 2.5 x 10<sup>6</sup> CD34+ cells/kg collected: 70 mg/m<sup>2</sup> IV once per day on days 1 & 2
 
−
'''Autologous stem cell infusion occurs 24 to 72 hours after the last dose of melphalan'''
 
−
</div>
 
−
<section end=e63043 />
 
−
</div>
 
−
===References===
 
−
# Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986 May;67(5):1298-301. [http://www.bloodjournal.org/content/67/5/1298 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3516252 PubMed]
 
−
# Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004 Jan 20;140(2):85-93. [http://annals.org/article.aspx?articleid=717091 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/14734330 PubMed]
 
−
<!-- Presented at the 55th American Society of Hematology Annual Meeting, New Orleans, LA, December 7-10, 2013, and the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milan, Italy, March 30 to April 2, 2014. -->
 
−
# Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP; IFM. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. [https://doi.org/10.1200/jco.2015.63.1929 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/27114594 PubMed]
 
−
==R-BEAM {{#subobject:8b88db|Regimen=1}}==
 
−
R-BEAM: '''<u>R</u>'''ituximab, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1, 500/300/1600/1600/140 {{#subobject:db487f|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJMoa1701769 Le Gouill et al. 2017 (LyMa)]
 
−
| style="background-color:#91cf61" |Non-randomized portion of RCT
 
−
|-
 
−
|}
 
−
''A minimum number of 2 × 10<sup>6</sup>/kg bw CD34-positive cells were required to proceed.''
 
−
<section begin=db487f />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Rituximab (Rituxan)]] 500 mg/m<sup>2</sup> IV once on day -8
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -7
 
−
*[[Etoposide (Vepesid)]] 400 mg/m<sup>2</sup> IV once per day on days -6 to -3
 
−
*[[Cytarabine (Ara-C)]] 400 mg/m<sup>2</sup> IV once per day on days -6 to -3
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -2
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=db487f />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2, 750/300/800/800/140 {{#subobject:9131e1|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1200/JCO.2012.45.9453 Vose et al. 2013 (BMT CTN 0401)]
 
−
|2006-2009
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[#B-BEAM_99|B-BEAM]]
 
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS24
 
−
|-
 
−
|}
 
−
<section begin=9131e1 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days -19 & -12
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -6
 
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV twice per day on days -5 to -2
 
−
*[[Cytarabine (Ara-C)]] 100 mg/m<sup>2</sup> IV twice per day on days -5 to -2
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -1
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=9131e1 />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #3, 750/300/1600/3200/140 {{#subobject:77f5a0|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1111/bjh.13234 Kirschey et al. 2014 (Mz-135)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
''A minimum number of 2 × 10<sup>6</sup>/kg bw CD34-positive cells were required to proceed.''
 
−
<section begin=77f5a0 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days -8 & -2
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -7
 
−
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV twice per day on days -6 to -3
 
−
*[[Cytarabine (Ara-C)]] 400 mg/m<sup>2</sup> IV twice per day on days -6 to -3
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -2
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=77f5a0 />
 
−
</div>
 
−
===References===
 
−
# '''BMT CTN 0401:''' Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, Horowitz M, Fisher R, Tomblyn M. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013 May 1;31(13):1662-8. Epub 2013 Mar 11. [https://doi.org/10.1200/JCO.2012.45.9453 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635682/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23478060 PubMed] NCT00329030
 
−
# '''Mz-135:''' Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematol. 2015 Mar;168(6):824-34. Epub 2014 Dec 28. [https://doi.org/10.1111/bjh.13234 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25546611 PubMed] NCT02099292
 
−
<!-- # '''Abstract:''' Steven Le Gouill, MD, PhD, Catherine Thieblemont, MD, PhD, Lucie Oberic, Krimo Bouabdallah, MD, Emmanuel Gyan, MD, PhD, Gandhi Damaj, MD, Vincent Ribrag, MD, Serge Bologna, MD, Remy Gressin, MD, Olivier Casasnovas, MD, Corinne Haioun, MD, PhD, Philippe Solal-Celigny, MD, Herve Maisonneuve, MD, Eric Van Den Neste, MD, PhD, Anne Moreau, MD, Marie C Bene, Gilles Salles, MD PhD, Hervé Tilly, MD, PhD, Thierry Lamy, MD, PhD and Olivier Hermine, MD, PhD. Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. Blood 2014 124:146. [http://www.bloodjournal.org/content/124/21/146 link to abstract] -->
 
−
# '''LyMa:''' Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. [https://doi.org/10.1056/NEJMoa1701769 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1701769/suppl_file/nejmoa1701769_appendix.pdf link to protocol] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/28953447 PubMed] NCT00921414
 
−
==R-TBI/Cy {{#subobject:9a5351|Regimen=1}}==
 
−
R-TBI/Cy: '''<u>R</u>'''ituximab, '''<u>T</u>'''otal, '''<u>B</u>'''ody, '''<u>I</u>'''rradiation, '''<u>Cy</u>'''clophosphamide
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:785614|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1111/bjh.13234 Kirschey et al. 2014 (Mz-135)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
''A minimum number of 2 × 10<sup>6</sup>/kg bw CD34-positive cells were required to proceed.''
 
−
<section begin=785614 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days -8 & -2
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 60 mg/kg IV once per day on days -3 & -2
 
−
====Radiotherapy====
 
−
*[[External_beam_radiotherapy|Total body irradiation (TBI)]]  with a total dose of 12 Gy over 3 days (days -6 to -4) in fractions
 
−
</div>
 
−
<section end=785614 />
 
−
</div>
 
−
===References===
 
−
# '''Mz-135:''' Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematol. 2015 Mar;168(6):824-34. Epub 2014 Dec 28. [https://doi.org/10.1111/bjh.13234 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25546611 PubMed] NCT02099292
 
−
==TAM6 {{#subobject:c810fd|Regimen=1}}==
 
−
TAM: '''<u>T</u>'''otal-body irradiation, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:4aee7c|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.bloodjournal.org/content/121/1/48.full Delarue et al. 2012]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=4aee7c />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Radiotherapy====
 
−
*[[External_beam_radiotherapy|Total body irradiation (TBI)]]  with a total dose of 10 Gy over 3 days using twice per day fractions
 
−
====Chemotherapy====
 
−
*[[Cytarabine (Ara-C)]] 1500 mg/m<sup>2</sup> IV every 12 hours for 2 days (total dose: 6000 mg/m<sup>2</sup>)
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once
 
−
====Supportive therapy====
 
−
"Antimicrobial prophylaxis and use of [[Filgrastim (Neupogen) | G-CSF]] or erythropoietin were permitted according to physician decision."
 
−
</div>
 
−
<section end=4aee7c />
 
−
</div>
 
−
===References===
 
−
# Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, Salles G, Van Hoof A, Casasnovas O, Brousse N, Lefrere F, Hermine O; Groupe d'Etude des Lymphomes de l'Adulte. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood. 2013 Jan 3;121(1):48-53. Epub 2012 Jun 20. [http://www.bloodjournal.org/content/121/1/48.full link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22718839 PubMed]
 
−
==TBI {{#subobject:1a2735|Regimen=1}}==
 
−
TBI: '''<u>T</u>'''otal '''<u>B</u>'''ody '''<u>I</u>'''rradiation
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:635694|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJM195904022601401 McGovern et al. 1959]
 
−
|1957-1958
 
−
| style="background-color:#ffffbe" |Pilot
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985418/ Stiff et al. 2013 (SWOG S9704)]
 
−
|1999-2007
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|[[#R-CHOP|R-CHOP]] x 8
 
−
| style="background-color:#1a9850" |Superior PFS
 
−
|-
 
−
|}
 
−
<section begin=635694 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Radiotherapy====
 
−
*[[External_beam_radiotherapy|Total body irradiation (TBI)]] in 1.5 Gy fractions twice per day on days -8 through -5 (total dose: 12 Gy)
 
−
</div>
 
−
<section end=635694 />
 
−
</div>
 
−
===References===
 
−
# McGovern JJ Jr, Russell PS, Atkins L, Webster EW. Treatment of terminal leukemic relapse by total-body irradiation and intravenous infusion of stored autologous bone marrow obtained during remission. N Engl J Med. 1959 Apr 2;260(14):675-83. [https://doi.org/10.1056/NEJM195904022601401 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13644566 PubMed]
 
−
# '''SWOG S9704:''' Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013 Oct 31;369(18):1681-90. [https://doi.org/10.1056/NEJMoa1301077 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985418/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24171516 PubMed] NCT00004031
 
−
==V-BEAM {{#subobject:d6ea18|Regimen=1}}==
 
−
V-BEAM: '''<u>V</u>'''elcade (Bortezomib), '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:7ef4f|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.bbmt.org/article/S1083-8791(14)00020-2 William et al. 2014]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
''Full details not available in abstract; to be added later.''
 
−
<section begin=7ef4f />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Bortezomib (Velcade)]] on days -11, -8, -5, -2
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]]
 
−
*[[Etoposide (Vepesid)]]
 
−
*[[Cytarabine (Ara-C)]]
 
−
*[[Melphalan (Alkeran)]]
 
−
</div>
 
−
<section end=7ef4f />
 
−
</div>
 
−
===References===
 
−
# William BM, Allen MS, Loberiza FR Jr, Bociek RG, Bierman PJ, Armitage JO, Vose JM. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma. Biol Blood Marrow Transplant. 2014 Apr;20(4):536-42. Epub 2014 Jan 14. [http://www.bbmt.org/article/S1083-8791(14)00020-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24434781 PubMed]
 
−
==Z-BEAM {{#subobject:19f0d0|Regimen=1}}==
 
−
Z-BEAM: '''<u>Z</u>'''evalin (Ibritumomab tiuxetan), '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1 {{#subobject:9aeafe|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1002/cncr.27418 Shimoni et al. 2012 (SHEBA-07-4466-AN-CTIL)]
 
−
|NR
 
−
| style="background-color:#1a9851" |Randomized Phase 2 (E-esc)
 
−
|[[#BEAM|BEAM]]
 
−
| style="background-color:#91cf60" |Seems to have superior OS
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943314/ Briones et al. 2013 (GELTAMO Z-BEAM LDCGB)]
 
−
|2008-2010
 
−
| style="background-color:#91cf61" |Phase 2
 
−
| style="background-color:#d3d3d3" |
 
−
| style="background-color:#d3d3d3" |
 
−
|-
 
−
|}
 
−
<section begin=9aeafe />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Rituximab (Rituxan)]] 250 mg/m<sup>2</sup> IV once on day -14, '''given first'''
 
−
====Radioconjugate therapy====
 
−
*[[Ibritumomab tiuxetan (Zevalin)|Ibritumomab tiuxetan & Yttrium-90 (Zevalin)]] 0.4 mCi/kg (maximum dose of 32 mCi) IV once on day -14, '''given second'''
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -6
 
−
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV once per day on days -5 to -2
 
−
*[[Cytarabine (Ara-C)]] 200 mg/m<sup>2</sup> IV every 12 hours on days -5 to -2
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -1
 
−
====Supportive therapy====
 
−
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day +4 (Shimoni et al. 2012) or day +7 (GELTAMO Z-BEAM LDCGB) until engraftment
 
−
*[[Valacyclovir (Valtrex)]] (dose not specified) for one month (Shimoni et al. 2012)
 
−
*[[Acyclovir (Zovirax)]] (dose not specified) for one month (Briones et al. 2013)
 
−
*[[Trimethoprim-Sulfamethoxazole (Bactrim DS)]] (dose/frequency not specified) for six months (3 months in GELTAMO Z-BEAM LDCGB)
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=9aeafe />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2 {{#subobject:e7f161|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.bbmt.org/article/S1083-8791(14)00473-X Fruchart et al. 2014 (ZBEAM2)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=e7f161 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Rituximab (Rituxan)]] 250 mg/m<sup>2</sup> IV once per day on days -21 & -14, '''given first on day -14'''
 
−
====Radioconjugate therapy====
 
−
*[[Ibritumomab tiuxetan (Zevalin)|Ibritumomab tiuxetan & Yttrium-90 (Zevalin)]] 0.4 mCi/kg (maximum dose of 32 mCi) IV once on day -14, '''given second'''
 
−
**Dose reduced to 0.3 mCi/kg if platelet count was greater than 100 x 10<sup>9</sup>/L and less than 150 x 10<sup>9</sup>/L.
 
−
====Chemotherapy====
 
−
*[[Carmustine (BCNU)]] 300 mg/m<sup>2</sup> IV once on day -7
 
−
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days -6 to -3
 
−
*[[Cytarabine (Ara-C)]] 200 mg/m<sup>2</sup> IV every 12 hours on days -6 to -3
 
−
*[[Melphalan (Alkeran)]] 140 mg/m<sup>2</sup> IV once on day -2
 
−
====Supportive therapy====
 
−
*"According to standard use"
 
−
'''Stem cells re-infused on day 0'''
 
−
</div>
 
−
<section end=e7f161 />
 
−
</div>
 
−
===References===
 
−
# Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol. 2007 Apr;35(4):534-40. [http://www.exphem.org/article/S0301-472X(07)00050-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17379063 PubMed]
 
−
# '''SHEBA-07-4466-AN-CTIL:''' Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012 Oct 1;118(19):4706-14. Epub 2012 Jan 17. [https://doi.org/10.1002/cncr.27418 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22252613 PubMed] NCT00491491
 
−
# '''GELTAMO Z-BEAM LDCGB:''' Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D. Autologous stem cell transplantation after conditioning with Yttrium-90 ibritumomab tiuxetan plus beam in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014 Mar;99(3):505-10. Epub 2013 Oct 25. [http://www.haematologica.org/content/99/3/505.full link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943314/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24162789 PubMed] EudraCT 2007-003198-22
 
−
# '''ZBEAM2:''' Fruchart C, Tilly H, Morschhauser F, Ghesquières H, Bouteloup M, Fermé C, Van Den Neste E, Bordessoule D, Bouabdallah R, Delmer A, Casasnovas RO, Ysebaert L, Ciappuccini R, Briere J, Gisselbrecht C. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2014 Dec;20(12):1905-11. Epub 2014 Jul 26. [http://www.bbmt.org/article/S1083-8791(14)00473-X link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25072780 PubMed] NCT00689169
 
−
=Low-dose conditioning regimens for cellular therapy, all lines of therapy=
 
−
==Bendamustine monotherapy {{#subobject:11f8b0|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:d4f6a0|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJMoa1804980 Schuster et al. 2018 (JULIET)]
 
−
|style="background-color:#91cf61"|Phase 2
 
−
|-
 
−
|}
 
−
''Note: Lymphodepleting chemotherapy may be omitted if a patient’s white blood cell count is less than or equal to 1 x 10<sup>9</sup>/L within 1 week prior to tisagenlecleucel infusion. This regimen is suggested if a patient experienced a previous grade 4 hemorrhagic cystitis with cyclophosphamide or demonstrates resistance to a previous cyclophosphamide-containing regimen.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2
 
−
</div></div>
 
−
===References===
 
−
<!-- # '''Abstract:''' Schuster SJ, Bishop MR, Tam C, et al. Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 in Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—an Interim Analysis. Hematological Oncology. 2017;35(S2):27. [https://doi.org/full/10.1002/hon.2437_6 link to abstract] -->
 
−
# '''JULIET:''' Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019 Jan 3;380(1):45-56. Epub 2018 Dec 1. [https://doi.org/10.1056/NEJMoa1804980 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30501490 PubMed] NCT02445248
 
−
##'''Update:''' Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 Oct;22(10):1403-1415. Epub 2021 Sep 10. [https://doi.org/10.1016/s1470-2045(21)00375-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34516954/ PubMed]
 
−
==CYVE {{#subobject:c60bd2|Regimen=1}}==
 
−
CYVE: '''<u>CY</u>'''tarabine & '''<u>VE</u>'''peside (Etoposide)
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:595c04|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5996391/ Maude et al. 2018 (ELIANA)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=595c04 />
 
−
''Note: This regimen is intended for patients with a history of grade 4 hemorrhagic cystitis from cyclophosphamide, or chemorefractory disease in the context of cyclophosphamide. CAR-T cells are to be given 2 to 14 days after completion of lymphodepleting therapy.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cytarabine (Ara-C)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 2
 
−
*[[Etoposide (Vepesid)]] 150 mg/m<sup>2</sup> IV once per day on days 1 to 3
 
−
</div>
 
−
<section end=595c04 />
 
−
</div>
 
−
===References===
 
−
# '''ELIANA:''' Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018 Feb 1;378(5):439-448. [https://doi.org/10.1056/NEJMoa1709866 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1709866/suppl_file/nejmoa1709866_protocol.pdf link to supplementary protocol] '''contains dosing details in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5996391/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29385370 PubMed] NCT02435849
 
−
==FC {{#subobject:866f6d|Regimen=1}}==
 
−
FC: '''<u>F</u>'''ludarabine & '''<u>C</u>'''yclophosphamide
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #1, 250/25 {{#subobject:31b4ca|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJMoa1804980 Schuster et al. 2018 (JULIET)]
 
−
|style="background-color:#91cf61"|Phase 2
 
−
|-
 
−
|}
 
−
''Note: Lymphodepleting chemotherapy may be omitted if a patient’s white blood cell count is less than or equal to 1 x 10<sup>9</sup>/L within 1 week prior to tisagenlecleucel infusion.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV once per day on days 1 to 3
 
−
*[[Cyclophosphamide (Cytoxan)]] 250 mg/m<sup>2</sup> IV once per day on days 1 to 3
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*Infuse [[Tisagenlecleucel (Kymriah)|tisagenlecleucel]] 2 to 11 days after completion of the lymphodepleting chemotherapy
 
−
</div></div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #2, 500/30, 2 doses of cyclophosphamide, 4 doses of fludarabine {{#subobject:de937a|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5996391/ Maude et al. 2018 (ELIANA)]
 
−
| style="background-color:#91cf61" |Phase 2
 
−
|-
 
−
|}
 
−
<section begin=de937a />
 
−
''Note: CAR-T cells are to be given 2 to 14 days after completion of lymphodepleting therapy.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV once per day on days 1 to 4
 
−
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 2
 
−
</div>
 
−
<section end=de937a />
 
−
</div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen variant #3, 500/30, 3 doses of cyclophosphamide, 3 doses of fludarabine {{#subobject:b295a4|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363293/ Locke et al. 2017 (ZUMA-1)]
 
−
| style="background-color:#91cf61" |Phase 1/2
 
−
|-
 
−
|}
 
−
<section begin=b295a4 />
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Fludarabine (Fludara)]] 30 mg/m<sup>2</sup> IV once per day on days -6 to -4
 
−
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days -6 to -4
 
−
</div>
 
−
<section end=b295a4 />
 
−
</div>
 
−
===References===
 
−
#'''ZUMA-1:''' Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017 Jan 4;25(1):285-295. Epub 2017 Jan 4. [https://doi.org/10.1016/j.ymthe.2016.10.020 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363293/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28129122 PubMed] NCT02348216
 
−
##'''Update:''' Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531-2544. Epub 2017 Dec 10. [https://doi.org/10.1056/NEJMoa1707447 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882485/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29226797 PubMed]
 
−
##'''Update:''' Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Jan;20(1):31-42. Epub 2018 Dec 2. [https://doi.org/10.1016/S1470-2045(18)30864-7 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733402/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/30518502 PubMed]
 
−
# '''ELIANA:''' Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018 Feb 1;378(5):439-448. [https://doi.org/10.1056/NEJMoa1709866 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1709866/suppl_file/nejmoa1709866_protocol.pdf link to supplementary protocol] '''contains dosing details in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5996391/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29385370 PubMed] NCT02435849
 
−
<!-- # '''Abstract:''' Schuster SJ, Bishop MR, Tam C, et al. Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 in Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—an Interim Analysis. Hematological Oncology. 2017;35(S2):27. [https://doi.org/full/10.1002/hon.2437_6 link to abstract] -->
 
−
# '''JULIET:''' Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019 Jan 3;380(1):45-56. Epub 2018 Dec 1. [https://doi.org/10.1056/NEJMoa1804980 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30501490 PubMed] NCT02445248
 
−
##'''Update:''' Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 Oct;22(10):1403-1415. Epub 2021 Sep 10. [https://doi.org/10.1016/s1470-2045(21)00375-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34516954/ PubMed]
 
−
[[Category:Autologous HSCT regimens]]
 
−
[[Category:Site-agnostic regimens]]
 

Latest revision as of 00:13, 18 June 2023

Retrieved from "https://hemonc.org/w/index.php?title=Staging_page&oldid=73776"